News & Updates

In patients with hepatocellular carcinoma (HCC), higher serum S-adenosylhomocysteine (SAH) concentrations may contribute to a shorter survival, regardless of the genetic variants of one-carbon metabolism key enzyme, according to a study.

Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.